Primary Cells Market Size

Global Primary Cells Market Overview

Primary Cells Market Size was valued at USD 1.83 Billion in 2023. The Global Primary Cells industry is projected to grow from USD 2.06 Billion in 2024 to USD 4.56 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.25% during the forecast period (2024 - 2032).

Increased cancer frequency, increasing government funding for cancer research, and building new infrastructure to support the healthcare industry are the key market drivers enhancing market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Primary Cells Market Trends

• Development of potential cancer medicines and treatments will boost market growth

Due to increased cancer research and the creation of novel cures and treatments, the demand for primary cells has been increasing. With no proven dependable cure and few known causes of its genesis, cancer has been the deadliest and most enduring type of sickness in the world. As a result, research into the disease has continued and expanded for many years. The field of cancer research has been greatly benefited and widened by advances in biochemistry and medically related apparatus, like improved microscopes and chemicals. The development of efficient therapeutics using primary cells to treat a range of immunodeficiency illnesses is propelling the worldwide market for primary cells at a rapid rate thanks to significant expenditures in R&D efforts. Medical researchers are continuously attempting to treat malignant malignancies utilizing primary cells from an animal or human tissue due to the rise of the biotechnology and biopharmaceutical sectors. The primary cell market is expanding because of the utilization of patient-derived samples in cutting-edge preclinical technologies including 3D cell cultures. Additionally, primary human cells are increasingly favored over animal cells for researching how cancer cells affect the human body. Thus, this factor is driving the market CAGR. 

Figure 1: Number of cancer cases by 2030

Source: Secondary and Primary Research, MRFR Database and Analyst Review

The global market for primary cells has been steadily expanding, related to the rise in cancer cases everywhere. Due to their advantages over cell lines, primary cells are employed for cancer cell discovery and medication screening, driving market expansion. Furthermore, because cancer is acknowledged as the leading cause of death worldwide, governments and private institutions all over the globe are quickly investing in new healthcare technologies for successful cancer treatment, providing momentum to the primary cell market expansion. Primary cells are used in extensive research activities to create pertinent medications and procedures, such as cell and regenerative therapies, to cure cancer patients. Thus, it is anticipated that this aspect will accelerate Primary Cells market revenue globally.

Primary Cells Market Segment Insights

Primary Cells Source Insights

Based on the Source, the Primary Cells Market segmentation includes Hematopoietic Cells, Skin Cells, Gastrointestinal Cells, Liver Cells, Lung Cells, and Skeletal and Muscle Cells. The Hematopoietic Cells segment held the majority share in 2022 in the Primary Cells Market data. This can be attributed to the rising prevalence of blood cancer and the increasing number of stem cell research projects. Hematopoietic cells are used to understand the biochemical pathways of tumor cells and the efficacy of different drugs. As a result, this segment accounts for the largest market share.

Primary Cells Type Insights

Based on type, the Primary Cells Market segmentation includes Human Primary Cells and Animal Primary cells. The Human primary cells segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. The main drivers promoting the growth of this market are the expanding use of primary human cells in the creation of innovative cancer medicines and the rising funding for cell therapy R&D.

Figure 2: Primary Cells Market, by Type, 2021 & 2032 (USD billion)Source: Secondary and Primary Research, MRFR Database and Analyst Review

Primary Cells End-user Insights

Based on End-user, the Primary Cells Market segmentation includes Pharmaceutical and Biotechnology Companies and Research Institutes. The Pharmaceutical and Biotechnology Companies segment dominated the Primary Cells market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. The product is being used by pharmaceutical and biotechnology firms for pharmaceutical drug discovery to treat genetic and autoimmune illnesses, damage, and inflammation. Pharmaceutical companies frequently use primary cells to test the cytotoxicity of novel medicines and drug carriers. The market need for primary cells has grown from this niche as an alternative to using animal testing models to test novel medications and chemicals. 

Primary Cells Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Primary Cells market accounted for USD 0.27 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. The primary cell culture market was dominated by North America, which accounted for the biggest revenue share of 45.80% in 2021 and is anticipated to maintain this pattern during the forecast period. The high cost of healthcare, expanding senior population, increasing prevalence of chronic illnesses, and support government financing are all contributing factors to the Region's rise. The Region's market is also expanding due to market participants' increased focus on developing novel cell culture applications, instrumentation, the availability of various cell types, and their cellular interactions.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: PRIMARY CELLS MARKET SHARE BY REGION 2021 (%)Source: Secondary and Primary Research, MRFR Database and Analyst Review

Throughout the projected period, the Asia Pacific Primary cells market is anticipated to have the quickest growth. The reduced prices for stem cell transplantation in the area, which also contribute to the strong demand, are the main cause of the rise. Significant R&D activities are also being carried out by researchers, which is another factor contributing to the expansion of the Region. For instance, in March 2020, scientists at China's Centre for Disease Control (CDC) propagated SARS-CoV-2 using lung airway cells grown in human tissue culture systems. Further, the China Primary Cells market held the largest market share, and the India Primary Cells market was the fastest growing market in the region.

Regarding worth, Europe's Primary cells market is now holding Third place. Europe continues to place a lot of emphasis on the healthcare sector. Many initiatives have been introduced to enhance the Region's medical services. The developed economies of Europe offer market participants appealing growth prospects. According to the Bureau for National Statistics, the gross domestic spending on R&D activities was more than xx billion euros in 2021. Moreover, the UK Primary Cells market held the largest market share, and the Germany Primary Cells market was the fastest-growing market in the Region.

Primary Cells Key Market Players & Competitive Insights

Major market players are investing a lot of money in R&D to expand their product portfolios, which will spur further market growth for the Primary Cells industry. With significant industry changes, including new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market participants are also undertaking various strategic activities to expand their global presence. In order to grow and remain in a market that is becoming more and more competitive, Primary Cells industry competitors must provide affordable products.

Manufacturing locally to cut operational costs is one of the main business tactics used by the Primary Cells industry to serve customers and increase the market sector. The Primary Cells industry has recently given medicine some of the most important advantages. The Primary Cells markets major players such as AllCells (US),  ZenBio Inc. (Research Triangle Park NC),   PromoCell (UK),  Thermo Fisher Scientific Inc. (US),  Cell Biologics Inc. (Chicago), STEMCELL Technologies Inc. (Canada),  Merck KGaA (Germany), American Type Culture Collection (ATCC), AG (Switzerland), and others are working on expanding the market demand by investing in research and development activities.

An American provider of scientific equipment, reagents, and consumables, as well as software services, is Thermo Fisher Scientific Inc. Thermo Fisher, headquartered in Waltham, Massachusetts, was created in 2006 by the union of Thermo Electron and Fisher Scientific. Thermo Fisher Scientific Inc., for instance, introduced a novel medium for developing human T cells for allogeneic cell treatments in January 2021. The new Gibco CTS OpTmizer Pro SFM aids in promoting the multiplication of donor T (lymphocyte) cells. It is a revolutionary media option for efficiently producing cost-effective cell treatments by focusing on the metabolism of healthy donors.

The Lonza Group is a Basel-based international manufacturer of products for the pharmaceutical, biotechnology, and nutrition industries. It has significant operations in North America, South Asia, and North Europe. Lonza was founded in the late 19th century in Switzerland with that name. Lonza and AllCells signed a private cooperation agreement in February 2019. This partnership was carried out to produce a wide variety of primary hematopoietic cells after commercialization. This collaboration increased Lonza's product line and gave cell biologists simple access to a variety of high-quality cells that were accessible and suitable for their study.

Key Companies in the Primary Cells market include

• AllCells (US)


• ZenBio Inc. (Research Triangle Park, NC)


• PromoCell (UK)


• Thermo Fisher Scientific Inc. (US)


• Cell Biologics Inc. (Chicago)


• STEMCELL Technologies Inc. (Canada)


• Merck KGaA (Germany)


• American Type Culture Collection (ATCC)


• AG (Switzerland)

Primary Cells Industry Developments

June 2018 Lonza introduced their new line of primary cells, which includes Kupffer cells, liver-derived endothelial cells, and hepatic stellate cells.

April 2018 British Columbia and Canada each contributed $45 million to STEMCELL Technologies, allowing the business to establish an advanced manufacturing plant.

 October 2020 iBio, Inc., a biotechnology business with headquarters in the United States, and Safi Biosolutions, Inc. announced a strategic partnership agreement to create growth factors and cytokines utilizing iBio's FastPharming System.

Primary Cells Market Segmentation

Primary Cells Source Outlook

• Hematopoietic Cells


• Skin Cells


• Gastrointestinal Cells


• Liver Cells


• Lung Cells


• Skeletal and Muscle Cells

Primary Cells Type Outlook

• Human Primary Cells


• Animal Primary Cells

Primary Cells End User Outlook

• Pharmaceutical and Biotechnology Companies


• Research Institutes

Primary Cells Regional Outlook

• 
  

  North America

  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  

  Europe

  
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America